IL1B and acute myeloid leukemia: Interestingly, targeting the IL-1 pathway with the multi-kinase inhibitor, pacritinib, which inhibits IRAK1/4, FLT3, and JAK2, highlights robust sensitivity despite adaptive resistance to therapies and significant AML cell death (174, 175).